Literature DB >> 9489596

The time of maximum effect for model selection in pharmacokinetic-pharmacodynamic analysis applied to frusemide.

M Wakelkamp1, G Alván, G Paintaud.   

Abstract

AIMS: Both indirect-response models and effect-compartment models are used to describe the pharmacodynamics of drugs when there is a delay in the time course of the pharmacological effect in relation to the concentration of the drug. The aim of this study was to investigate whether the time of maximum response after single-dose administration at different dose levels could be used to distinguish between these models and to select the most appropriate pharmacokinetic-pharmacodynamic model for frusemide.
METHODS: Three doses of frusemide, 10, 25 and 40 mg were given as rapid intravenous infusions to five healthy volunteers. Urine samples were collected for 5 h after dosing. Volume and sodium losses were isovolumetrically replaced with an intravenous rehydration fluid. Diuresis and natriuresis were modelled for all three doses simultaneously, applying both an indirect-response model and an effect-compartment model with the frusemide excretion rate as the pharmacokinetic input.
RESULTS: The observed time of maximum diuretic and natriuretic response significantly increased with dose. This increase was well predicted by the indirect-response model, whereas the modelling with the effect-compartment model led to a poor prediction of the peaks. There was no difference between the observed and predicted time of maximum diuretic and natriuretic response using the indirect-response model, whereas the time of maximum response predicted by the effect-compartment model was significantly earlier than the time observed for the 25 mg (P < 0.05) and 40 mg (P < 0.05) doses.
CONCLUSIONS: The time of maximum response to frusemide was better described using an indirect-response model than an effect-compartment model. Studying the time of maximum response after administration of different single doses of a drug may be used as a selective tool during pharmacokinetic-pharmacodynamic modelling.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9489596      PMCID: PMC1873996          DOI: 10.1046/j.1365-2125.1998.00637.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Further notes on physiologic indirect response models.

Authors:  L B Sheiner; D Verotta
Journal:  Clin Pharmacol Ther       Date:  1995-08       Impact factor: 6.875

2.  Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration.

Authors:  M Wakelkamp; G Alván; J Gabrielsson; G Paintaud
Journal:  Clin Pharmacol Ther       Date:  1996-07       Impact factor: 6.875

Review 3.  Loop diuretics.

Authors:  R Greger; P Wangemann
Journal:  Ren Physiol       Date:  1987

4.  A new enzymatic assay of chloride in serum.

Authors:  T Ono; J Taniguchi; H Mitsumaki; F Takahata; A Shibuya; Y Kasahara; F Koshimizu
Journal:  Clin Chem       Date:  1988-03       Impact factor: 8.327

5.  A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data.

Authors:  D Verotta; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1995-02

6.  Mechanism-based pharmacodynamic modeling.

Authors:  G Levy
Journal:  Clin Pharmacol Ther       Date:  1994-10       Impact factor: 6.875

7.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects.

Authors:  W J Jusko; H C Ko
Journal:  Clin Pharmacol Ther       Date:  1994-10       Impact factor: 6.875

Review 8.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

9.  Renal tubular secretion and effects of furosemide.

Authors:  B Odlind; B Beermann
Journal:  Clin Pharmacol Ther       Date:  1980-06       Impact factor: 6.875

10.  Routine methods in toxicology and therapeutic drug monitoring by high performance liquid chromatography: III. A rapid microscale method for determination of furosemide in plasma and urine.

Authors:  S P Sood; V I Green; Z M Norton
Journal:  Ther Drug Monit       Date:  1987-12       Impact factor: 3.681

View more
  8 in total

1.  The influence of frusemide formulation on diuretic effect and efficiency.

Authors:  M Wakelkamp; A Blechert; M Eriksson; K Gjellan; C Graffner
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Indirect-response modeling of desmopressin at different levels of hydration.

Authors:  T Callréus; J Odeberg; S Lundin; P Höglund
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

3.  Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of imipenem in healthy rats.

Authors:  A Dupuis; W Couet; J Paquereau; S Debarre; A Portron; C Jamois; S Bouquet
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.

Authors:  H Derendorf; B Meibohm
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

5.  A dynamical systems analysis of the indirect response model with special emphasis on time to peak response.

Authors:  Lambertus A Peletier; Johan Gabrielsson; Jacintha den Haag
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

Review 6.  Methodological issues in pharmacokinetic-pharmacodynamic modelling.

Authors:  E Bellissant; V Sébille; G Paintaud
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

7.  The influence of drug input rate on the development of tolerance to frusemide.

Authors:  M Wakelkamp; G Alván; H Scheinin; J Gabrielsson
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

8.  Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models.

Authors:  Wilhelmus E A de Witte; Vivi Rottschäfer; Meindert Danhof; Piet H van der Graaf; Lambertus A Peletier; Elizabeth C M de Lange
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-05-18       Impact factor: 2.745

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.